A number of other equities research analysts have also recently commented on PRGO. Oppenheimer began coverage on shares of Perrigo in a research note on Thursday, September 7th. They issued an outperform rating and a $88.00 price objective on the stock. CIBC began coverage on shares of Perrigo in a research note on Thursday, September 7th. They set an outperform rating and a $88.00 price target on the stock. BidaskClub raised shares of Perrigo from a strong sell rating to a sell rating in a research note on Saturday, September 9th. Cantor Fitzgerald raised their price target on shares of Perrigo from $93.00 to $107.00 and gave the stock an overweight rating in a research note on Tuesday, September 12th. Finally, Royal Bank of Canada reaffirmed a sell rating and set a $64.00 price target on shares of Perrigo in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $92.00.
Perrigo (NYSE PRGO) opened at $91.08 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72. Perrigo has a 12 month low of $63.68 and a 12 month high of $92.04. The firm has a market cap of $12,596.79, a price-to-earnings ratio of -9.94, a PEG ratio of 1.73 and a beta of 0.70.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 19th. Stockholders of record on Friday, December 1st were issued a dividend of $0.16 per share. The ex-dividend date was Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. Perrigo’s payout ratio is currently -6.99%.
In related news, EVP John Wesolowski sold 450 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $83.09, for a total value of $37,390.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Todd W. Kingma sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the transaction, the vice president now owns 19,565 shares in the company, valued at approximately $1,731,893.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,051 shares of company stock worth $355,370. Insiders own 6.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of PRGO. Vanguard Group Inc. raised its stake in shares of Perrigo by 2.1% during the second quarter. Vanguard Group Inc. now owns 14,874,096 shares of the company’s stock valued at $1,123,292,000 after purchasing an additional 299,328 shares during the period. Franklin Resources Inc. grew its position in shares of Perrigo by 117.7% during the second quarter. Franklin Resources Inc. now owns 8,109,742 shares of the company’s stock worth $612,448,000 after buying an additional 4,383,903 shares in the last quarter. State Street Corp grew its position in shares of Perrigo by 1.7% during the second quarter. State Street Corp now owns 6,757,086 shares of the company’s stock worth $510,294,000 after buying an additional 112,287 shares in the last quarter. Greenlight Capital Inc. grew its position in shares of Perrigo by 14.8% during the third quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock worth $245,572,000 after buying an additional 374,032 shares in the last quarter. Finally, Parnassus Investments CA grew its position in shares of Perrigo by 7.1% during the third quarter. Parnassus Investments CA now owns 2,257,000 shares of the company’s stock worth $191,055,000 after buying an additional 150,000 shares in the last quarter. Hedge funds and other institutional investors own 83.29% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.